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Abstract
Background: There is evidence that dyslipidemia is associated with chronic kidney disease (CKD).
Experimental studies have established that lipids are damaging to the kidney and animal intervention
studies show statins attenuate this damage. Small clinical trials, meta-analyses, observational studies
and post-hoc analyses of cardiovascular intervention studies all support the concept that statins can
reduce kidney damage in humans. Based on this background, a double blind randomized placebo
controlled trial was designed to assess the effectiveness of atorvastatin 10 mg on slowing the
progression of kidney disease in a population of patients with CKD.
Method/Design: The Lipid lowering and Onset of Renal Disease (LORD) trial is a three-year,
single center, multi-site, double blind, randomized, placebo controlled trial. The primary outcome
measure is kidney function measured by eGFR calculated by both Modification of Diet in Renal
Disease (MDRD) and Cockcroft and Gault equations. Secondary outcome measures include kidney
function measured by 24-hour urine creatinine clearance and also 24-hour urinary protein
excretion, markers of oxidative stress, inflammation and drug safety and tolerability.
Discussion:  The results of this study will help determine the effectiveness and safety of
atorvastatin and establish its effects on oxidative stress and inflammation in patients with CKD.
Trial Registration: ANZCTRN012605000693628
Background
End stage kidney disease (ESKD) is a major health prob-
lem resulting in a considerable increase in morbidity and
mortality, decreased quality of life, and substantial health
care costs [1]. Clinical trials attempting to slow the pro-
gression of kidney disease should be a major focus of
research. As treatments directed at primary kidney dis-
eases are few, therapies have been directed towards slow-
ing the progression of kidney disease by controlling
hypertension, using angiotensin converting enzyme
inhibitors (ACEI's) and angiotensin receptor blockers
(ARB's) and lowering the protein intake in the diet [2-6].
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Dyslipidemia has been identified as an independent risk
factor for the progression of kidney disease [7]. The dele-
terious effect of hyperlipidemia on the progression of kid-
ney disease is based on a number of lines of evidence.
In a large number of different animal models hyperlipi-
demia has been clearly shown to accelerate the progres-
sion of kidney disease [8]. There is extensive evidence for
the processes involved in lipid induced kidney damage,
where multiple mechanisms appear to be involved but a
common initiation by hyperlipidemia is present. In addi-
tion, intervention studies have assessed the effects of stat-
ins on limiting kidney damage, again, in a variety of
animal models [9,10]. In these studies statins had a bene-
ficial effect on kidney structure and function. Not only did
statins reduce proteinuria, they attenuated inflammatory
processes and prevented histological changes of inflam-
mation and fibrosis in the kidney.
A comprehensive search of the literature has found 25
randomized controlled trials (RCT's) reporting on the
effects of statins on kidney function however these have
been mostly of small size, short duration, with narrow
inclusion and exclusion criteria, often conducted on
patients with normal or stable kidney function, using a
variety of statins and doses, or with poor concealment and
often no placebo group. Some were also potentially
affected by the inclusion of other lipid lowering agents.
The results of these are best summarized in the meta-anal-
yses described below.
The large cardiovascular clinical trials such as GREACE,
CARE and TNT provide data on a significant number of
subjects exposed to statins [11-13]. These studies how-
ever, were primarily designed to assess cardiovascular out-
comes in subjects presenting with cardiac disease or who
were at a high risk of cardiac disease. They were not specif-
ically designed to test kidney function outcomes. Post-hoc
sub-analyses are commonly performed on these large tri-
als to extract maximum benefit from the available data
that takes years to accumulate at a high cost. Wang et al
reported that such analyses introduce challenges and may
lead to "overstated and misleading results" [14]. The most
important conclusion that can be drawn from these cardi-
ovascular studies is that subjects with kidney dysfunction
who meet the cardiovascular criteria of these trials, which
for most include a prior myocardial infarction, will do
well from the kidney function perspective when treated
with a statin. In addition there are no data available from
these cardiovascular trials regarding the kidney disease
diagnosis thus no conclusions can be made regarding how
to treat any specific kidney disease type.
There have been two published meta-analyses reporting
on the effects of statins on kidney function, one by Fried
et al [15], and the most recent, reported by Sandhu et al
(2006), that includes most of the 25 RCT's mentioned
above [16]. The subject numbers are substantially larger in
the Sandhu analysis as the larger cardiovascular trials were
included. This however is a limitation as this inclusion
mixes prospective studies with post-hoc, sub-studies of
major randomized controlled trials. Thus the authors'
conclusions must be interpreted with caution. The meta-
analyses support the suggestion that statins have a benefi-
cial effect on kidney function. The Sandhu et al meta-anal-
ysis also implies that statins have a more protective effect
on kidney function in subjects recruited with a cardiovas-
cular disease and that the more potent statin, atorvastatin,
has a greater effect on protecting kidney function than the
less potent statins such as pravastatin, fluvastatin, lovasta-
tin and simvastatin [16]. Based on the need for further
clarification and investigation of the role of statins in
slowing CKD progression the LORD Trial was designed.
This trial is intended to have inclusion criteria that
reflected common clinical practice to enable the results to
be as clinically relevant as possible.
Methods/Design
Study Design and Setting
The study was a single centre, multi-site three-year, double
blind randomized placebo controlled trial in subjects
with CKD. The study was conducted in North and North
West Tasmania and the principal investigator is the sole
nephrologist in this region.
Ethical Considerations
The Tasmanian Statewide Scientific Committee and the
Tasmanian Statewide Ethics Committee approved the
LORD Trial. The Ethics Committee will be provided with
annual reports of the LORD trial progress and will
promptly receive all adverse event reports.
Identification of Eligible Patients
The principal investigator and the clinical trial coordina-
tors will screen the medical records of patients prior to
their attendance at the renal clinics. The serum creatinine
is measured and the results available prior to the clinic.
Eligible patients will have a copy of the Ethics Committee
approved patient information sheet placed in the medical
record. The principal investigator will then explain the
study during the clinical consultation. After the explana-
tion the subject will be provided with a patient informa-
tion sheet and informed consent form. The subject will
then be asked to take this away with them and arrange-
ments will be made to follow up via a telephone call. If the
subject agrees to participate, they will sign the consent
form with an independent person signing as a witness to
this process.BMC Nephrology 2008, 9:4 http://www.biomedcentral.com/1471-2369/9/4
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Eligibility
Inclusion criteria are; age 18 – 85 years, serum creatinine
> 120 μmol/l at the screening visit, history of CKD, signed
informed consent. Subjects will be excluded if they are
already taking lipid-lowering medication or if they are
females of childbearing age, able to conceive and not
using contraception. Other exclusion criteria are: subjects
with acute liver disease or unexplained persistent eleva-
tions of serum transaminases, or a history of alcoholism,.
Patients will also be excluded if they have had a seizure
within a year of study entry, have a hypersensitivity to
atorvastatin or one of its components or are participating
in, or propose to participate in, another clinical investiga-
tional drug study within 30 days prior to study entry.
Randomization
The Clinical Trial Pharmacist at the Launceston General
Hospital, who is independent of the study team, will per-
form the randomization. Subjects will also be stratified
according to three diagnostic groups; glomerulonephritis,
diabetes and other diagnoses. Computer generated ran-
dom numbers will be placed in blocks of 10 by the Clini-
cal Trial Pharmacist and related to a series of drug code
numbers. Each drug code assignment block will refer to
one of the stratification groups. Data recorded will
include the drug code number, which becomes the sub-
jects LORD trial identification number, the patient hospi-
tal record number, the date of allocation as well as the
diagnosis. The sheet containing the blocks of drug code
numbers are given to the clinical trial coordinator who
thus is blinded to the allocation performed by the phar-
macist. Once the diagnosis is confirmed by the principal
investigator the clinical trial coordinator selects the next
available drug code number from the relevant stratifica-
tion block according to diagnostic grouping. The drug
code number is then written on the prescription form and
given to the subject who then presents it to the pharmacy.
This enables the pharmacist (independent of the trial
pharmacist) to dispense from the appropriate randomiza-
tion group. The subject receives a specific purpose num-
bered LORD Trial plastic container with tablets enclosed,
which are indistinguishable whether they contain atorvas-
tatin 10 mg or identical placebo. The randomization code
is kept sealed in an opaque envelope in the Launceston
General Hospital Pharmacy Department and an identical
copy is kept at an off-site location of one of the associate
investigators for the duration of the study.
Study Medication and Dosing
Pfizer Pharmaceuticals, New York provided the atorvasta-
tin 10 mg and identical placebo, which were shipped in
containers from New York. Tablets will be checked to
ensure they will not exceed their expiry date at any stage
of their prescription to subjects. They will then be placed
in number coded containers so it is not possible to distin-
guish, other than with the code, which container has pla-
cebo or atorvastatin.
Primary Objective and Primary Outcome Measure
The primary objective of the LORD trial is to assess the
effect of atorvastatin 10 mg on the rate of decline of kid-
ney function in subjects with CKD. The primary outcome
measure will be the rates of decline in eGFR (ml/min/1.73
m2/month) measured by MDRD and Cockcroft Gault
equations.
The hypothesis is that atorvastatin 10 mg will significantly
slow the rate of decline of kidney function (eGFR) in sub-
jects with CKD.
The selection of the primary outcome measure was based
on the following issues: 1) the widespread use of this
marker in similar clinical trials [17-23], 2) other measures
including "hard" end points such as commencement of
dialysis, transplantation and death were considered how-
ever trials that have used such hard end points typically
recruit patients with more advanced kidney disease and in
larger numbers in order to show an effect of the therapy
over 2 – 5 years [2] Furthermore, although hard end
points are indicators of a drug's efficacy in reducing cardi-
ovascular events or preserving kidney function, they do
not assess the impact of a treatment on altering the natural
history of earlier stages of CKD. For clinical trials of sub-
jects with all but the most advanced renal disease, use of
intermediate end points of CKD progression is the only
practical option for assessment of treatment efficacy and
effectiveness [24], 3) intermediate endpoints that were
also considered for the major outcome measure included
changes in creatinine clearance, serum creatinine, pro-
teinuria or albuminuria. However measures of serum cre-
atinine and creatinine clearance have been argued to be
less sensitive markers of the progression of CKD [25]. Fur-
thermore, proteinuria and albuminuria may be affected
by dietary changes and are therefore problematic in a
longer term (three-year) study and 4) other more accurate
measures of kidney function such as 51CrEDTA, 99TcDTPA
and cystatin C were considered either too expensive and/
or time consuming for subjects in this study population.
Secondary Objectives, Outcome Measures and Sub Studies
The secondary objectives (and their associated measures)
will assess the effects of atorvastatin 10 mg on 24-hour
urine creatinine clearance and protein excretion, the
requirement for ESKD management, self reported health
(SF-36 questionnaire), physical activity levels (Active Aus-
tralia questionnaire) nutritional status (four-day diet
diary), cardiovascular events, mortality, hospital admis-
sions, drug safety and tolerability. In addition, further sec-
ondary objectives included assessing the effects of
atorvastatin on measures of inflammation (plasma C reac-BMC Nephrology 2008, 9:4 http://www.biomedcentral.com/1471-2369/9/4
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tive protein, tumor necrosis factor-alpha and interleukin
6) and oxidative stress (plasma isoprostanes). Sub-studies
on smaller groups will also assess the effect of atorvastatin
on arterial stiffness and cognitive function.
Visit One (baseline data)
The LORD study flow is summarized in Figure 1 and the
study evaluations are outlined in table 1. After obtaining
informed consent patients will be provided with a LORD
Trial pathology request form, a four-day diet diary and a
24-hr urine collection bottle. They will be asked to attend
the pathology laboratory at least seven days before their
first trial visit (approximately three months later) to have
a fasting blood sample collected and hand in a 24-hr urine
sample. At the first trial visit, additional data will be
obtained from the medical records (medical history, med-
ications), measures of height, weight and blood pressure
will be made and two questionnaires will be completed
(SF 36 and Active Australia). At this visit they will provide
their completed four-day diet diary and be given their next
appointment time for trial visit two that will be approxi-
mately three months after visit one. At the completion of
visit one, the clinical trial coordinator will provide
patients with a prescription containing their drug code
number. They then present thus to the pharmacy depart-
ment to obtain their first three-month supply of trial med-
ication as described in the section on randomization.
Subjects will be instructed to take one tablet each day at
any time of the day, either with or without food. The same
instructions are provided on the medication container. At
this visit the subjects will be given a LORD trial pathology
request form and a 24-hr urine collection bottle. They will
be asked to attend the pathology laboratory at least seven
days prior to their next visit to have a fasting blood sample
collected and hand in a 24-hr urine sample. They are given
their next appointment time that will be no longer than
three months after this visit. The capture of data occurs at
the scheduled study visits and are transcribed onto case
recoerd forms (CRFs) for entry into a specifically designed
LORD Trial database.
Additional Trial Visits
These visits will occur with the principal investigator and
the clinical trial coordinator every three months for a total
of three years. Subjects will be required to visit the pathol-
ogy laboratory and have a fasting blood sample collected
and hand in a 24-hr urine collection at least 7 days before
each of these visits. They are also required to return the
tablet container with the remaining tablets and they will
be issued with a prescription form so they can obtain a
new container with a further three-month supply of trial
medication from the pharmacy department. At these visits
they are given a routine medical examination where blood
pressure, height and weight are measured. Every nine
months during this period they are given a four-day diet
dairy and required to return it at the next visit. Every 9
months they are also asked to complete the SF-36 and
Active Australia questionnaires. At each visit they are given
their next visit appointment time.
Adherence to Study Medication
Trial visits are conducted every three months and as a con-
sequence, sufficient medication is included in the con-
tainer to last for this interval. However as a crosscheck of
the subjects adherence to drug therapy, each container has
100 tablets placed in it for each trial visit and the subjects
are not informed that the containers have additional tab-
lets. At each trial visit the subject is required to return the
container. Two separate tablet counts are then conducted
one by the trial coordinator and the trial pharmacist per-
Table 1: Baseline and ongoing data collection
Baseline data and follow-up data every three months for 36 months
eGFR Cockcroft and Gault
eGFR MDRD
24 hour urine creatinine clearance
24 hour urine protein
Weight and blood pressure
Adverse events and concomitant therapy
Laboratory tests
Hematology
Biochemistry
Oxidative stress measures
Inflammation measures
Lipid profile
Baseline data and follow-up data at 9,18,27 and 36 months
SF 36
Active Australia Questionnaire
Four-day diet diaryBMC Nephrology 2008, 9:4 http://www.biomedcentral.com/1471-2369/9/4
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forms a separate count. This enables a check on adherence
to therapy by calculating the difference between 100 and
the days of therapy and comparing this with number of
tablets left in the container.
Withdrawal from Study
Subjects will be withdrawn from the study at their request,
without prejudice, as documented and explained at the
time of consenting. Patients who withdraw will be
encouraged to consent to allow access to their pathology
results for the remainder of the trial duration to enable an
intention to treat data analysis.
Sample size calculation
The following assumptions were made for the sample size
calculation. The rate of decline of eGFR, based on the
expected population to be recruited in the LORD trial and
a similar trial [3], was assumed to be 0.29 ml/min/1.73
m2/month. To demonstrate a clinically significant
improvement, based on the REIN study, we expected a dif-
ference in rate of eGFR decline of 40%, between atorvas-
tatin treated subjects and controls [2]. Thus we assumed
that subjects in the atorvastatin group would have a
monthly decline of eGFR of 0.17 ml/min/1.73 m2. The
standard deviation was assumed to be twice the decline
(0.24) [3]. Therefore, it was estimated that the study
required 63 subjects per group for alpha to equal 0.05
(two-tailed test) and a power (1-β) of 0.80. To achieve this
we aimed to recruit 200 subjects into the LORD trial,
which allowed for a dropout rate of 60%.
Statistical analysis
The primary analysis will use an intention to treat
approach and the secondary analysis will use an on treat-
ment approach. The rate of decline of eGFR in ml/min/
1.73 m2/month will be compared between atorvastatin
treated subjects and the placebo group using a two-tailed
independent t test. Significance will be deemed p < 0.05.
Discussion
The objective of the LORD Trial is to assess whether ator-
vastatin 10 mg can slow the progression of CKD. Measures
of oxidative stress and inflammation will be used to assess
whether these are concomitantly affected by this statin
treatment. If statins slow the progression of CKD, then
most CKD patients may benefit from this treatment. Pre-
vious studies have been conducted in this area but have
been either smaller, open labeled or short duration. Other
studies, such as the SHARP study [26], seek to assess the
same question however they include the cholesterol
absorption inhibitor ezetimibe in the treatment group,
which may confuse the nature of the potential effective
agent. The measure of eGFR every three months during
the three-year trial is another strength of this protocol. We
predict atorvastatin will slow the progression of CKD.
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